AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 211 min read$PHVS

Schikan Johannes Gerardus Christiaan Petrus sold $7.0M of PHVS

Schikan Johannes Gerardus Christiaan Petrus sold 200,000 shares of Pharvaris N.V. (PHVS) at $35.00 ($7.00M total) on 2026-09-17.

Original reporting
SEC EDGAR · Schikan Johannes Gerardus Christiaan Petrus
Published Sep 21, 2026, 8:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 8:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PHVS
Bearish
medium confidence
Mentioned
$PHVS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSBearishLow
01

Why it matters

Direct insider sell could signal negative sentiment.

02

Market read

Primary disclosure of a sizable insider sale.

03

What to watch

No immediate catalyst; sale could be routine liquidity need.

Relevance 6/10Novelty 6/10Timing: post-filing 2026-09-21

Background

SEC Form 4 filing discloses insider transaction.

Company-level read

Ticker impact

$PHVSBearishMedium confidence
Context

Director sold 200,000 shares for $7M, reducing his stake to 115,167 shares.

Expected impact

Potential downward pressure over next few days.

Evidence & confidence

Large sale by a director suggests possible concerns about valuation.

Market effects

Sector

May affect biotech sector sentiment as insider sales are monitored.

Regional

Limited to US biotech investors.

Global

Low global impact.

Counterpoint

What could challenge this read

Insider may be diversifying, not necessarily bearish.

Key entities

  • Director
    Schikan Johannes Gerardus Christiaan Petrus

    Insider selling shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PHVS insider trading history →

Related articles

SEP 12
$BCRXHigh

BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease

BioCryst Pharmaceuticals (BCRX) shares fell 9% on Tuesday, their worst day in over 6 months, after competitor Pharvaris (PHVS) reported positive late-stage trial results for a rare swelling disorder treatment. PHVS shares rose 7% during trading and 3% after-hours. Orladeyo, BioCryst's approved treatment, generated over $2B in revenue since 2020 and is expected to bring in $625M-$645M this year. BioCryst is also developing a second treatment, navenibart, with late-stage data expected in 2027.

stocktwits.com2 min
SEP 10
$PHVSMedAI 9/10

Pharvaris at Cantor Fitzgerald conference: oral HAE push gains momentum

Pharvaris (PHVS) presented at the Cantor Fitzgerald conference, highlighting 87% reduction in HAE attacks with deucrictibant in Phase III trials. The company plans an on-demand launch in April 2025 and a prophylaxis filing in the first half of 2025. Management addressed safety concerns and outlined a broad commercial strategy. Shares are up 62% over the past year, with analysts setting price targets between $42 and $79.

investing.com3 min
SEP 9
$PHVSHighAI 8/10

Wedbush Reaffirms Outperform Rating On Pharvaris; PT $42 After Positive Phase 3 CHAPTER-3 Data

Wedbush reaffirmed an Outperform rating and $42 price target for Pharvaris (PHVS) after positive Phase 3 data for deucrictibant XR in preventing hereditary angioedema attacks. The study met primary and secondary endpoints, showing an 83% reduction in attack rate. PHVS reported a Q2 2026 net loss of €47.8M and cash of €318M. The stock is up 7.35% on the day.

rttnews.com2 min